118 related articles for article (PubMed ID: 29745087)
1. High Mobility Group Box 1 (HMGB1) expression in gastric adenocarcinomas.
Suren D; Arda Gokay A; Sayiner A
J BUON; 2018; 23(2):422-427. PubMed ID: 29745087
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo.
Zhang J; Kou YB; Zhu JS; Chen WX; Li S
Int J Oncol; 2014 Apr; 44(4):1268-76. PubMed ID: 24481712
[TBL] [Abstract][Full Text] [Related]
3. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer.
Guo J; Zu G; Zhou T; Xing J; Wang Z
Clin Transl Oncol; 2015 Oct; 17(10):788-94. PubMed ID: 26022133
[TBL] [Abstract][Full Text] [Related]
5. Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients.
He W; Tang B; Yang D; Li Y; Song W; Cheang T; Chen X; Li Y; Chen L; Zhan W; Li W; He Y
World J Surg Oncol; 2013 Jul; 11():161. PubMed ID: 23866030
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer.
Fang J; Ge X; Xu W; Xie J; Qin Z; Shi L; Yin W; Bian M; Wang H
J Cell Physiol; 2020 Apr; 235(4):3438-3446. PubMed ID: 31621076
[TBL] [Abstract][Full Text] [Related]
7. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma.
Liu Z; Dou C; Yao B; Xu M; Ding L; Wang Y; Jia Y; Li Q; Zhang H; Tu K; Song T; Liu Q
Oncotarget; 2016 Jun; 7(24):36909-36923. PubMed ID: 27191994
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo.
Zhang J; Zhu JS; Zhou Z; Chen WX; Chen NW
Oncol Rep; 2012 May; 27(5):1511-9. PubMed ID: 22246223
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.
Uchino S; Tsuda H; Maruyama K; Kinoshita T; Sasako M; Saito T; Kobayashi M; Hirohashi S
Cancer; 1993 Dec; 72(11):3179-84. PubMed ID: 7902202
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of tristetraprolin and human antigen R promotes gastric cancer progressions partly by upregulation of the high-mobility group box 1.
Wang H; Chen Y; Guo J; Shan T; Deng K; Chen J; Cai L; Zhou H; Zhao Q; Jin S; Xia J
Sci Rep; 2018 May; 8(1):7080. PubMed ID: 29728635
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas.
Bao G; Qiao Q; Zhao H; He X
World J Surg Oncol; 2010 Jun; 8():52. PubMed ID: 20579387
[TBL] [Abstract][Full Text] [Related]
13. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.
Feng A; Tu Z; Yin B
Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258
[TBL] [Abstract][Full Text] [Related]
14. Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus.
Zhou Y; Liu SX; Zhou YN; Wang J; Ji R
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1339-1350. PubMed ID: 33629304
[TBL] [Abstract][Full Text] [Related]
15. Role of Glycated High Mobility Group Box-1 in Gastric Cancer.
Kishi S; Nishiguchi Y; Honoki K; Mori S; Fujiwara-Tani R; Sasaki T; Fujii K; Kawahara I; Goto K; Nakashima C; Kido A; Tanaka Y; Luo Y; Kuniyasu H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068442
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.
Yao X; Zhao G; Yang H; Hong X; Bie L; Liu G
J Cancer Res Clin Oncol; 2010 May; 136(5):677-84. PubMed ID: 19898867
[TBL] [Abstract][Full Text] [Related]
17. High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer.
Yue Y; Zhou T; Gao Y; Zhang Z; Li L; Liu L; Shi W; Su L; Cheng B
Tumour Biol; 2017 Mar; 39(3):1010428317694312. PubMed ID: 28347236
[TBL] [Abstract][Full Text] [Related]
18. The effect of HMGB1 on the clinicopathological and prognostic features of cervical cancer.
Li P; Xu M; Cai H; Thapa N; He C; Song Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30962261
[TBL] [Abstract][Full Text] [Related]
19. Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma.
Singh MK; Singh L; Pushker N; Sen S; Sharma A; Chauhan FA; Kashyap S
Pathol Oncol Res; 2015 Sep; 21(4):1237-42. PubMed ID: 26118980
[TBL] [Abstract][Full Text] [Related]
20. Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of P‑glycoprotein expression in gastric adenocarcinoma cells.
Yin Y; Li W; Deng M; Zhang P; Shen Q; Wang G; Tao K
Mol Med Rep; 2014 Apr; 9(4):1439-43. PubMed ID: 24549588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
